Brought to you by 
Baxter announces plans to spin off biopharma operations as Baxalta
19 May 2016
Executive Summary
Baxter International Inc., which announced in March its intention to split into two publicly traded companies--one focused on biopharmaceuticals, the other on medical products--in a tax-free distribution to shareholders, revealed it plans to spin off the Baxter BioScience biopharma operations as Baxalta Inc., a publicly traded company that will list on the NYSE under the symbol BXLT.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter announces plans to spin off biopharma operations as Baxalta
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice